Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study

Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study

Abstract: We report final analysis results from the PILOT study of lisocabtagene maraleucel (liso-cel) for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Sixty-one adults with R/R LBCL who had received 1 previous line of therapy and met ≥1 hematopoietic stem cell transplantati...

Full description

Saved in:
Bibliographic Details
Main Authors: Alison Sehgal, Daanish Hoda, Peter A. Riedell, Nilanjan Ghosh, Mehdi Hamadani, Gerhard C. Hildebrandt, John E. Godwin, Patrick M. Reagan, Nina D. Wagner-Johnston, James Essell, Rajneesh Nath, Scott R. Solomon, Rebecca Champion, Edward Licitra, Suzanne Fanning, Neel K. Gupta, Victor A. Chow, Brenda Yuan, Zhi Yang, Ken Ogasawara, Jerill Thorpe, Leo I. Gordon
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:Blood Advances
Online Access:http://www.sciencedirect.com/science/article/pii/S247395292500254X
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

http://www.sciencedirect.com/science/article/pii/S247395292500254X

Similar Items